Olema Pharmaceuticals (OLMA) Operating Leases (2021 - 2025)

Olema Pharmaceuticals (OLMA) has 5 years of Operating Leases data on file, last reported at $69000.0 in Q4 2025.

• On a quarterly basis, Operating Leases fell 73.15% year-over-year to $69000.0 in Q4 2025; TTM through Dec 2025 was $69000.0, a 73.15% decrease from a year earlier, with the FY2025 full-year figure at $69000.0, down 73.15% from the prior year.
• Operating Leases for Q4 2025 stood at $69000.0, down from $310000.0 in the prior quarter.
• Over the last five years, Operating Leases for OLMA reached as high as $2.4 million in Q4 2021 and fell as low as $69000.0 in Q4 2025.
• Historically, Operating Leases has averaged $1.1 million across 5 years, with a median of $1.2 million in 2023.
• Across the five-year window, Operating Leases retreated 2.69% in 2023 and slumped 89.32% in 2025, its largest moves.
• Year by year, Operating Leases stood at $2.4 million in 2021, then slumped by 34.27% to $1.5 million in 2022, then fell by 7.81% to $1.4 million in 2023, then plunged by 82.02% to $257000.0 in 2024, then tumbled by 73.15% to $69000.0 in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $69000.0 in Q4 2025, $310000.0 in Q3 2025, and $602000.0 in Q2 2025.